Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0LESTV |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-PSMA1 |
|||||
| Synonyms |
Anti-PSMA1
Click to Show/Hide
|
|||||
| Antigen Name | Glutamate carboxypeptidase 2 (FOLH1) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
PSMA1 -LD12 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.23 nM
|
Positive PSMA expression (PSMA +++/++) | ||
| Method Description |
In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
|
||||
| In Vitro Model | Prostate carcinoma | LNCaP-C4.2 cells | CVCL_4782 | ||
PSMA 1-LD6 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.85 nM
|
Positive PSMA expression (PSMA +++/++) | ||
| Method Description |
In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
|
||||
| In Vitro Model | Prostate carcinoma | LNCaP-C4.2 cells | CVCL_4782 | ||
PSMA 1-LD4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.18 nM
|
Positive PSMA expression (PSMA +++/++) | ||
| Method Description |
In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
|
||||
| In Vitro Model | Prostate carcinoma | LNCaP-C4.2 cells | CVCL_4782 | ||
PSMA 1-LD3 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.23 nM
|
Positive PSMA expression (PSMA +++/++) | ||
| Method Description |
In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
|
||||
| In Vitro Model | Prostate carcinoma | LNCaP-C4.2 cells | CVCL_4782 | ||
PSMA 1-LD5 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.79 nM
|
Positive PSMA expression (PSMA +++/++) | ||
| Method Description |
In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
|
||||
| In Vitro Model | Prostate carcinoma | LNCaP-C4.2 cells | CVCL_4782 | ||